RAREUltragenyx Pharmaceutical Inc.vs its industry peers
A metric-by-metric comparison of Ultragenyx Pharmaceutical Inc. against SPDR S&P Biotech ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RARE본 종목 | $1.4B#15 | — | — | 2.1x#1 | 20.2%#5 | -1.1%#7 | -79.5%#2 | — | — | — | -49.5%#15 | — |
| MRNA | $63.1B#1 | — | 9.3x#8 | 32.5x#3 | -39.9%#7 | 20.8%#5 | -158.1%#4 | -41.7%#11 | -54.6%#3 | — | 531.8%#4 | — |
| TWST | $9.8B#4 | — | 21.9x#12 | 25.9x#2 | 20.3%#4 | 62.8%#1 | -36.2%#1 | -17.4%#7 | -41.4%#2 | — | 476.3%#6 | — |
| ORKA | $6.5B#10 | — | 5.8x#3 | — | — | -25.9%#8 | — | -9.5%#4 | — | — | 504.8%#5 | — |
| KYMR | $9.9B#3 | — | 6.5x#6 | 251.3x#6 | -16.7%#6 | 39.1%#2 | -891.1%#6 | 20.6%#1 | — | — | 146.3%#9 | — |
| VKTX | $3.4B#13 | — | 8.4x#7 | — | — | -227.1%#15 | — | -88.1%#13 | — | — | 27.3%#13 | — |
| PRAX | $8.7B#7 | — | 6.5x#4 | — | -100.0%#9 | -65.6%#11 | — | -22.6%#9 | — | — | 605.0%#2 | — |
| ERAS | $5.4B#12 | — | 14.8x#9 | — | — | 23.0%#4 | — | -34.4%#10 | — | — | 821.9%#1 | — |
| RVMD | $42.2B#2 | — | 16.2x#10 | — | — | -88.5%#13 | — | -43.4%#12 | — | — | 349.4%#7 | — |
| RYTM | $6.8B#8 | — | 66.2x#13 | 35.9x#4 | 45.8%#3 | 24.6%#3 | -101.2%#3 | -0.2%#3 | -133.8%#4 | — | 3.0%#14 | — |
| CGON | $6.7B#9 | — | 6.5x#5 | 1659.3x#7 | 254.7%#2 | -82.9%#12 | -4722.1%#7 | -15.6%#6 | -18.8%#1 | — | 100.7%#10 | — |
| SLS | $2.3B#14 | — | 16.9x#11 | — | -100.0%#9 | 13.0%#6 | — | -19.5%#8 | — | — | 580.2%#3 | — |
| PCVX | $9.0B#6 | — | 3.3x#1 | — | — | -65.2%#10 | — | -0.0%#2 | — | — | 95.6%#11 | — |
| DNTH | $5.7B#11 | — | 4.8x#2 | 2780.6x#8 | -67.3%#8 | -91.1%#14 | -8739.3%#8 | -13.9%#5 | — | — | 160.3%#8 | — |
| CYTK | $9.7B#5 | — | — | 110.4x#5 | 376.6%#1 | -33.2%#9 | -695.4%#5 | — | — | — | 47.1%#12 | — |
Peer set: top holdings of XBI (SPDR S&P Biotech ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-18.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice